Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell 10Hematologic Diseases 7Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 2Leukemia, Lymphoid 2Leukemia, B-Cell 2Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1

Interventions

ofatumumab 10ibrutinib 6Rituximab 5acalabrutinib 4Cyclophosphamide 3spebrutinib 2pirtobrutinib 2obinutuzumab 2navitoclax 2fludarabine phosphate 2Tablets 2Lenalidomide 2KW-2478 2Chlorambucil 2Antigens, CD19 2ARQ531 2venetoclax 1tirabrutinib 1pomalidomide 1pivalyloxymethyl butyrate 1immunotoxin HA22 1idelalisib 1idecabtagene vicleucel 1fludarabine 1dinaciclib 1bempegaldesleukin 1Vincristine 1Rabeprazole 1Prednisone 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, B-Cell × pirtobrutinib × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05254743 2026-04-20

BRUIN-CLL-314

Eli Lilly and Company

Phase 3 Recruiting
662 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡